Clinical trials: HTLV-II Infections
Acquired Immunodeficiency Syndrome, Blood Donors
Retrovirus Epidemiology Donor Study-II (REDS-II)
To conduct epidemiological, laboratory, and survey research on volunteer blood donors within the United States to ensure the safety and availability of the United States' blood supply.
- Conditions
- Acquired Immunodeficiency Syndrome, Blood Donors, Blood Transfusion, HIV Infections
- Trial name
- NCT00097006
- Sponsor
- National Heart, Lung, and Blood Institute (NHLBI)
HTLV-I Infection, T Cell Leukemia
Anti-Tac for Treatment of Leukemia
The purpose of the study was to determine: (1) the toxicity and maximum tolerated dose (MTD) of humanized anti-Tac (daclizumab), (Zenapax(Registered Trademark)) in patients with adult T-cell leukemia/lymphoma (ATL); (2) to define…
- Trial name
- NCT00001941
- Testing
- daclizumab
- Where
- United States
- Volunteers
- 34 people
- Sponsor
- National Cancer Institute (NCI)
Acquired Immunodeficiency Syndrome, Blood Donors
Retrovirus Epidemiology Donor Study I (REDS I)
To conduct a multicenter epidemiologic study of the human retroviruses HIV-1, HIV-2, HTLV-I, and HTLV-II in volunteer blood donors from areas of the United States that were reportedly at high and medium or low risk for HIV.
- Conditions
- Acquired Immunodeficiency Syndrome, Blood Donors, Blood Transfusion, HIV Infections
- Trial name
- NCT00005278
- Sponsor
- National Heart, Lung, and Blood Institute (NHLBI)